Immune-Mediated Thrombocytopenia (ITP) in Dogs — Management Guide

Practical, evidence-based guide to canine immune-mediated thrombocytopenia: causes, diagnosis, drug protocols (steroids, vincristine, IVIG), monitoring, relapse and living-with advice.

Quick Overview

• What it is: Immune-mediated thrombocytopenia (ITP) is an immune disorder in which a dog’s immune system destroys platelets, the blood cells responsible for clotting. This leads to bleeding (petechiae, bruising, nosebleeds, melena) and increased risk of life‑threatening hemorrhage.
• Who’s at risk: Any dog can develop ITP; it is most commonly seen in young to middle‑aged dogs but can occur at any age. Certain breeds (Cocker Spaniels, Springer Spaniels and others) are reported more often in case series. ITP can be primary (immune-mediated without an identifiable trigger) or secondary (associated with drugs, infections, neoplasia or vaccination).
• Prognosis: With prompt diagnosis and therapy most dogs respond. Reported initial response rates to immunosuppressive therapy are commonly 60–85%; however severe bleeding at presentation, concurrent immune diseases, or secondary causes worsen outcome.

Pathophysiology — explained simply

Platelets are small blood cells that stick together to form clots and stop bleeding. In ITP, the dog’s immune system makes antibodies that bind platelets. Antibody‑coated platelets are removed by the spleen (macrophage phagocytosis) or destroyed in circulation, and antibody‑coated platelet precursors in the bone marrow can be impaired. The result is a low circulating platelet count (thrombocytopenia) and a tendency to bleed.

Two important clinical facts:

• Platelet counts can fall quickly, so a normal platelet count one day doesn’t exclude ITP if bleeding signs develop later.
• Bone marrow often shows normal or increased megakaryocytes (platelet precursors) in primary ITP — the marrow is trying to compensate.

Breed-specific risk factors and prevalence

ITP is reported across breeds. Published case series show overrepresentation of Cocker Spaniels and Springer Spaniels in some populations, but any breed (and mixed breeds) can be affected. Female dogs are sometimes reported slightly more often. Exact prevalence is low (ITP is uncommon), but it is one of the more common immune-mediated cytopenias seen by veterinary internists.

Clinical signs and severity grading

Common signs reflect bleeding from small vessels due to low platelets:

• Petechiae (tiny red dots in gums, skin) and ecchymoses (larger bruises)
• Gingival bleeding, nosebleeds (epistaxis)
• Blood in vomit (hematemesis), dark tarry stools (melena), or frank blood in stools
• Pale mucous membranes, weakness, lethargy
• In severe cases: collapse, tachycardia, shock, or intracranial hemorrhage with neurologic signs

• Normal: ~200,000–500,000/µL
• Mild thrombocytopenia: 100,000–150,000/µL
• Moderate: 50,000–100,000/µL
• Severe: <50,000/µL — bleeding risk increases
• Critical/spontaneous bleeding risk: <20,000–30,000/µL

Diagnostic approach

Goals: confirm thrombocytopenia, rule out secondary causes, and identify life‑threatening bleeding.

Essential steps:

• Full physical exam (look for petechiae, ecchymoses, wounds)
• CBC with platelet count (and blood smear to verify true thrombocytopenia — platelets clump can artifactually lower automated counts)
• Coagulation panel (PT, aPTT) if bleeding or before invasive procedures
• Chemistry panel and urinalysis to evaluate organ function and hydration
• Tick‑borne disease testing (Ehrlichia, Anaplasma, Babesia) and other infectious disease testing as indicated (PCR/serology)
• Medication and vaccine history (some drugs and recent vaccinations can trigger secondary ITP)
• Thoracic/abdominal imaging (radiographs/abdominal ultrasound) if concern for neoplasia or severe bleeding
• Bone marrow aspiration/biopsy if platelet production suspected to be impaired or if unusual features present

Treatment options

Treatment has three parallel goals: stop active bleeding, reduce immune destruction of platelets, and support the patient while platelet counts recover.

Medical therapy

1) Corticosteroids — first-line

• Prednisone/prednisolone PO: commonly 2 mg/kg/day divided BID (or ~60 mg/m2/day). Some protocols use 1–2 mg/kg/day. Dexamethasone may be used IV at 0.15–0.3 mg/kg once daily for short pulses.
• Mechanism: broad immunosuppression — reduce antibody production and splenic macrophage activity.
• Side effects: polyuria, polydipsia, polyphagia, GI ulceration, increased infection risk.

• Azathioprine: 2 mg/kg once daily for 2–3 months (not used in cats); monitor liver enzymes and CBC.
• Cyclosporine: 5–10 mg/kg/day divided BID; effective for many steroid‑refractory dogs; monitor for GI side effects.
• Mycophenolate mofetil (MMF): 10–20 mg/kg PO BID — increasingly used as an alternative to azathioprine.
• Leflunomide: 2–4 mg/kg/day (in some refractory cases).

3) Vincristine (short course, for rapid platelet rise)

• Dose: 0.02 mg/kg IV as a single dose (some clinicians use up to 0.04 mg/kg but 0.02 mg/kg is commonly cited).
• Effect: accelerates release of platelets from marrow and impairs macrophage platelet destruction — can increase platelet count in 24–48 hours in many dogs.
• Use: reserved for severe thrombocytopenia (typically <10–30k) or active bleeding to shorten the high‑risk period.
• Caution: vincristine is a chemotherapeutic — handle carefully; watch for GI signs, bone marrow suppression with repeated doses.

• Dosing ranges 0.5–1 g/kg as a single dose (costly).
• Effect: transient blocking of Fc receptors and rapid platelet increase in many dogs — useful in severe bleeding or when rapid response is needed.
• Effect often transient (days to weeks) but can be lifesaving.

• Whole blood or platelet‑rich plasma for life‑threatening hemorrhage.
• Packed RBC transfusion for anemia from bleeding.
• GI protectants (misoprostol, famotidine) if on high‑dose steroids or GI bleeding.
• Strict cage rest, minimize trauma.

• Splenectomy: considered in refractory or relapsing cases when medical therapy fails. Remission rates vary; splenectomy may reduce platelet destruction if the spleen is the primary site. Decision should be individualized and discussed with a specialist.

• Thrombopoietin receptor agonists (eltrombopag, romiplostim) are used in human ITP and reported in veterinary literature for refractory cases; availability/cost and lack of large‑scale studies limit routine use.

Monitoring response and tapering

• Hospitalize and monitor daily platelet counts until a clear upward trend is seen. Platelet increases are often seen within 3–7 days after starting treatment; vincristine or IVIG can shorten this to 24–72 hours.
• Response definitions commonly used:

• Typical monitoring schedule:

Tapering steroids

• Once platelets are in a safe range and stable (commonly >150,000/µL for 1–2 weeks), begin a slow steroid taper: reduce dose by ~25% every 1–2 weeks while monitoring platelets. Rapid tapering increases relapse risk.
• If relapse occurs during taper, return to the last effective dose and consider adding a second immunosuppressant.

Relapse management

Relapse is common. Key steps:

• Confirm true thrombocytopenia (repeat CBC and blood smear).
• Reinstitute effective prior dose of corticosteroids immediately.
• Add or change second-line immunosuppressant (azathioprine, cyclosporine, MMF, leflunomide) if not already used.
• Consider repeat vincristine or IVIG if life‑threatening bleeding.
• Re-evaluate for secondary causes (infections, drugs, neoplasia).
• For frequent relapses despite therapy, consider splenectomy or referral for advanced care.

Prognosis and quality of life

• Many dogs respond and return to an excellent quality of life with appropriate therapy. Initial response rates to therapy are commonly reported in the 60–85% range; overall survival to discharge in hospitalized patients varies but can be roughly 70–80% in published series.
• Long‑term remission is achievable, but some dogs require months to years of therapy or long‑term low‑dose immunosuppression.
• Dogs with severe bleeding at presentation, concurrent IMHA (Evan’s syndrome), or underlying secondary causes have a worse prognosis.

Living with ITP — practical daily tips

• Keep your dog calm and avoid rough play, stairs, jumping, or contact with other animals while platelets are low.
• Use a leash on walks; avoid sidewalks with rough surfaces and areas where a fall could cause injury.
• Avoid NSAIDs and corticosteroid‑incompatible drugs unless prescribed by your vet. Ask before giving any over‑the‑counter medications or supplements.
• Check gums, eyes, and stool daily for any new bleeding (petechiae, red spots, black/tarry stools).
• Maintain scheduled recheck appointments and blood tests — early detection of relapse improves outcome.
• Keep vaccinations up to date before ITP develops; after recovery, your vet will advise on safe timing for future vaccinations.

When to see your vet urgently

Seek immediate veterinary care if your dog has any of the following:

• New or worsening nosebleed, persistent bleeding from a wound, or large bruises
• Black, tarry stools or visible blood in stool or vomit
• Weakness, collapse, rapid breathing, or pale gums
• Seizures, sudden blindness, or neurologic signs (possible intracranial bleeding)
• Platelet count confirmed under 20,000–30,000/µL or previously stable dog becomes suddenly symptomatic

Sources and further reading

• ACVIM Consensus Statement: Diagnosis and treatment guidelines for immune-mediated thrombocytopenia in dogs — Journal of Veterinary Internal Medicine (ACVIM). (primary reference)
• Garden OA, et al. Immune-mediated thrombocytopenia in small animals: a review of therapy and monitoring recommendations. Veterinary Clinics of North America: Small Animal Practice.
• Clinical studies on vincristine and IVIG support for rapid platelet recovery in canine ITP (see Journal of Veterinary Internal Medicine literature).

Frequently Asked Questions